Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Quetiapine
Drug ID BADD_D01888
Description Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder.[L8546] Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [Clozapine] and [Olanzapine].[A2189]
Indications and Usage Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.[L8546] Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.[A185438,A185447,T685]
Marketing Status approved
ATC Code N05AH04
DrugBank ID DB01224
KEGG ID D08456
MeSH ID D000069348
PubChem ID 5002
TTD Drug ID D0H7KF
NDC Product Code 0310-0530; 16729-145; 16729-149; 16714-453; 16714-454; 0093-8163; 50228-380; 0310-0280; 0310-0283; 60687-327; 65862-877; 68001-182; 68001-183; 68001-185; 80425-0107; 16729-146; 16729-150; 0310-0282; 60687-338; 63629-2479; 63629-2481; 65862-875; 70518-0752; 71093-136; 71205-402; 16729-147; 16714-455; 16714-457; 0093-8162; 42291-695; 42291-698; 42291-700; 43547-020; 0310-0272; 0310-0274; 0310-0278; 0310-0284; 68001-181; 70518-0239; 0310-0279; 60687-382; 65862-874; 71093-137; 0615-7987; 0310-0505; 43547-019; 50090-2830; 60687-349; 60687-371; 63629-2478; 63629-2480; 63629-2482; 63629-7116; 71093-138; 0615-7986; 0615-8119; 16714-452; 16714-456; 0093-8166; 33342-135; 43547-519; 71093-135; 72789-255; 80425-0143; 0093-2063; 0093-8164; 42291-699; 43547-520; 43547-522; 43547-523; 50090-2338; 50228-382; 50228-383; 0310-0271; 68001-184; 70518-0289; 71093-139; 16729-148; 29300-309; 50090-4788; 53002-1516; 0310-0275; 0310-0281; 60687-360; 65862-876; 70518-0570; 71205-026; 71610-702; 0310-0515; 0093-8165; 29300-308; 29300-310; 29300-311; 29300-312; 33342-136; 42291-696; 43547-021; 68001-180; 68788-7186; 70518-2828; 0615-7988; 0310-0520; 0310-0540; 33342-137; 42291-697; 43547-518; 43547-521; 50228-384; 65862-873; 71205-401; 0615-8118; 33342-134; 43547-022; 50228-381; 53002-1529
UNII BGL0JSY5SI
Synonyms Quetiapine Fumarate | Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-, (E)-2-butenedioate (2:1) (salt) | Seroquel | ICI 204,636 | ICI-204636 | ICI204636 | ICI 204636 | Quetiapine | 2-(2-(4-dibenzo(b,f)(1,4)thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol
Chemical Information
Molecular Formula C21H25N3O2S
CAS Registry Number 111974-69-7
SMILES C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Post-traumatic stress disorder19.06.06.0020.000120%Not Available
Poverty of speech19.19.02.007; 17.02.08.0200.000082%Not Available
Small for dates baby18.04.02.0020.000136%Not Available
Thrombocytopenia neonatal18.04.03.005; 01.08.01.0100.000055%Not Available
Tremor neonatal18.04.04.012; 17.01.06.0100.000082%Not Available
Violence-related symptom19.05.01.0220.000055%Not Available
Umbilical cord abnormality18.04.14.0030.000055%Not Available
Peripartum cardiomyopathy18.02.04.004; 02.04.01.0110.000082%Not Available
Imminent abortion18.01.04.0050.000055%Not Available
Asherman's syndrome21.07.01.014; 12.02.14.0040.000055%Not Available
Bradycardia neonatal18.04.07.004; 02.03.02.0190.000055%Not Available
Ballismus17.01.02.0170.000055%Not Available
Negative thoughts19.15.02.012--Not Available
Sopor17.02.04.021; 19.02.04.0020.004524%Not Available
Communication disorder19.19.01.0080.000082%Not Available
Spider vein24.10.04.003; 23.06.03.0060.000055%Not Available
Tachyphrenia19.10.03.010; 17.03.03.0070.000213%Not Available
Excessive eye blinking17.17.02.010; 06.05.01.0040.000185%Not Available
Anaemia of pregnancy18.02.02.012; 14.13.02.003; 01.03.01.0060.000082%Not Available
Sleep-related eating disorder19.02.03.012; 14.03.01.012; 17.15.02.0090.000480%Not Available
Herbal interaction08.06.03.0050.000055%Not Available
Distributive shock24.06.02.0220.000109%Not Available
Seizure like phenomena17.12.03.0300.000055%Not Available
Hyporesponsive to stimuli17.02.05.0570.000082%Not Available
Poor feeding infant18.04.06.006; 14.03.02.0220.000082%Not Available
Disorganised speech19.19.02.005; 17.02.08.0170.000283%Not Available
Selective eating disorder19.09.01.012; 14.03.02.0240.000191%Not Available
Attention deficit hyperactivity disorder19.21.04.0040.000185%Not Available
Dilated cardiomyopathy02.04.01.0170.000218%Not Available
Drug use disorder19.07.06.0120.000147%Not Available
The 25th Page    First    Pre   25 26    Next   Last    Total 26 Pages